Memantine

Generic Name
Memantine
Brand Names
Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
Drug Type
Small Molecule
Chemical Formula
C12H21N
CAS Number
19982-08-2
Unique Ingredient Identifier
W8O17SJF3T
Background

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication

Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions
Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

Treatment With Namenda in Women at Risk for Cognitive Decline

Not Applicable
Completed
Conditions
Dementia
Interventions
Drug: Namenda
First Posted Date
2005-10-20
Last Posted Date
2017-06-14
Lead Sponsor
Stanford University
Target Recruit Count
22
Registration Number
NCT00242632
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Memantine and Down's Syndrome

First Posted Date
2005-10-18
Last Posted Date
2006-02-20
Lead Sponsor
King's College London
Target Recruit Count
180
Registration Number
NCT00240760
Locations
🇬🇧

Northgate Hospital, Morpeth, Northumberland, United Kingdom

🇬🇧

Monyhull Hall Road, Birmingham, United Kingdom

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

First Posted Date
2005-10-10
Last Posted Date
2014-07-23
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
613
Registration Number
NCT00235716
Locations
🇺🇸

VA Medical Center, Bay Pines, Bay Pines, Florida, United States

🇺🇸

VA Medical Center, Miami, Miami, Florida, United States

🇺🇸

VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States

and more 11 locations

Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

Phase 2
Completed
Conditions
Dementia
First Posted Date
2005-09-20
Last Posted Date
2013-05-03
Lead Sponsor
Nantes University Hospital
Target Recruit Count
52
Registration Number
NCT00200538
Locations
🇫🇷

Martine Vercelletto, Nantes, France

Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial

Phase 4
Conditions
Aphasia
Stroke
First Posted Date
2005-09-20
Last Posted Date
2005-09-20
Lead Sponsor
Gabinete Berthier y Martínez
Target Recruit Count
30
Registration Number
NCT00196703
Locations
🇪🇸

Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES) University of Malaga, Malaga, Spain

A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

Phase 4
Completed
Conditions
Frontotemporal Lobar Degeneration
First Posted Date
2005-09-16
Last Posted Date
2012-11-12
Lead Sponsor
University of California, San Francisco
Registration Number
NCT00187525

Memantine in Systemic Lupus Erythematosus

Not Applicable
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Placebo
Drug: Memantine
First Posted Date
2005-09-16
Last Posted Date
2008-03-07
Lead Sponsor
Johns Hopkins University
Target Recruit Count
61
Registration Number
NCT00181298
Locations
🇺🇸

Johns Hopkins Lupus Center, 1830 East Monument Street, Suite 7500, Baltimore, Maryland, United States

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

Not Applicable
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo Oral Capsule
Drug: memantine
First Posted Date
2005-09-16
Last Posted Date
2019-09-27
Lead Sponsor
Stanford University
Target Recruit Count
11
Registration Number
NCT00186498
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults

Phase 4
Completed
Conditions
Depression
Interventions
Other: Placebo
Drug: Memantine
First Posted Date
2005-09-16
Last Posted Date
2018-01-17
Lead Sponsor
Eric Lenze
Target Recruit Count
35
Registration Number
NCT00183729
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Memantine in Patients With Chronic Glaucoma

Phase 3
Completed
Conditions
Open-Angle Glaucoma
First Posted Date
2005-09-15
Last Posted Date
2010-11-04
Lead Sponsor
Allergan
Target Recruit Count
1179
Registration Number
NCT00168350
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy